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Abstract
Background: Chronic liver disease (CLD) is a major health burden worldwide. Liver cirrhosis, a form of CLD is the
fifth most common cause of death in the UK. Acute-on-chronic liver failure (ACLF) is the result of an acute insult
superimposed on patients with liver cirrhosis as a result of precipitating events such as infection or bleeding. ACLF
has a high associated mortality as a result of multi-organ failure. The only effective treatment for CLD is liver
transplantation, but the treatment is limited by shortage of donor organs. As a result, alternative treatments such as
cell therapies have been studied in patients with liver diseases. This study will systematically review the evidence on
clinical effectiveness of cell therapies in patients.
Methods: All types of study design that investigate the effectiveness of cell therapies (haematopoietic, mesenchymal
and unsorted cell types) of autologous or allogeneic origin and/or the use of granulocyte colony-stimulating factor in
patients with CLD including ACLF will be included (except case reports). Both autologous and allogenic cell types will
be included. The primary outcomes of interest are survival, model for end-stage liver disease score, quality of life and
adverse events. Secondary outcomes include liver function tests, Child-Pugh score and events of liver decompensation.
A literature search will be conducted in the following databases: MEDLINE, MEDLINE in Process, EMBASE and Cochrane
Library (CENTRAL, CDSR, DARE, HTA databases). Trial registers will be searched for ongoing trials, as will conference
proceedings. Reference lists of relevant articles and systematic reviews will be screened. Randomised controlled trial
(RCT) evidence is likely to be scant; therefore, controlled trials and concurrently controlled observational studies will be
primarily analysed and uncontrolled observational studies will be analysed where primary outcomes are not reported in
the control studies or where uncontrolled studies have longer follow-up. Initial screening of studies will be carried by
one reviewer with a proportion checked by another reviewer. Full-text selection will be performed by two reviewers
independently against the pre-defined selection criteria. The data collection and the risk of bias assessment will be
completed by one reviewer and counter checked by another reviewer for all selected studies. Where appropriate, data
will be meta-analysed for each study design, therapy and outcome. Data specifically on ACLF will be treated as a
subgroup.
Discussion: This systematic review will identify the available evidence on the effectiveness of cell therapies in patients
with CLD and in ACLF subgroup. The findings will aid decision-making by clinicians and health service leaders.
Systematic review registration: PROSPERO CRD42016016104
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Background
Introduction on the underlying disease
Chronic liver disease (CLD) is a major health burden
worldwide, with 29 million people in Europe affected by
this condition [1]. Liver cirrhosis, also known as end-
stage CLD, is a slow progressive disease in which normal
liver tissue is replaced by fibrous tissue as a result of in-
jury such as alcohol excess or viral hepatitis. Liver cir-
rhosis is the fifth most common cause of death in
England and Wales after heart disease, cancer, stroke
and respiratory disease [2]. Mortality from patients with
liver cirrhosis is rising, and it is expected that it will
double in the next 20 years [2]. Mortality is usually a re-
sult of complications of liver cirrhosis or from liver can-
cer/hepatocellular carcinoma (HCC). Complications of
liver cirrhosis (known as decompensation) present as an
intermittent or persistent altered mental state (hepatic
encephalopathy), or manifestations of portal hyperten-
sion such as fluid accumulation in the abdomen (asci-
tes), or bleeding from porto-systemic collateral varices.
Liver cirrhosis is a recognised risk factor for the develop-
ment of HCC. HCC is the fifth most common cause of
cancer in Europe and constitutes 70–90 % of all cases of
primary liver cancer [2]. Common causes of liver cirrho-
sis are listed in Table 1.
Acute-on-chronic liver failure (ACLF) is an acute
deterioration of patients with liver cirrhosis that is
precipitated by a physiological insult (e.g. infection)
[3, 4]. It carries a worse prognosis than un-triggered
decompensation of liver cirrhosis. Patients require
more intensive monitoring and management as they
are less likely to recover and readily progress towards
multi-organ failure [5]. The main differences between
decompensated liver cirrhosis and ACLF are the po-
tential to recover and the progression towards multi-
organ failure. Increasingly, ACLF is being considered
as a discrete disease entity within liver cirrhosis or
CLD [6]. The progression of liver disease is illustrated
in Fig. 1.
Assessment of underlying liver disease
The severity of the liver disease is assessed by clinical as-
sessment, non-invasive imaging and biochemical blood
tests known as liver function tests (transaminase blood
tests, bilirubin, albumin and international normalised ra-
tio (INR). Blood test results and clinical features are
used to calculate composite risk scores that can predict
the survival of patients. The two commonly used scoring
systems are model for end-stage liver disease (MELD)
and Child-Pugh score (CPS).
The MELD score is an objective assessment of patients
with liver cirrhosis and is calculated using a combination
of blood tests: creatinine, serum bilirubin and INR. The
MELD score correlates to the severity of underlying
CLD and predicts transplant-free survival [7, 8]; it can
thus be used to stratify a patient’s need for liver trans-
plantation (LT) within the next 3 months [8, 9]. MELD
score is calculated from using this formulation: 9.5 × In
[Creatinine (9 mg/dL)] + 3.78 × In [Bilirubin (mg/dL)] +
11.2 × In (INR)+ 6.43 [9]. The score ranged from mini-
mum of 6 (mild disease) to maximum of 40 (severe dis-
ease) [10]. Patients with a score of 40 have a 300-fold
increased risk of mortality waiting for a transplant com-
pared to patients with a score of less than 12 [8, 11].
CPS is calculated from both objective parameters
(serum bilirubin, INR or prothrombin time, serum albu-
min) and subjective parameters (clinical assessment of
ascites and hepatic encephalopathy) [12, 13]. The score
varies between 7 and 15, and the mortality is increased
with a higher CPS [14]. The parameters for scoring
Child-Pugh are mentioned in Table 2.
Table 1 Causes of chronic liver disease
Alcohol excess
Viral hepatitis (B and C)
Non-alcoholic fatty liver disease
Autoimmune mediated
• Autoimmune hepatitis
• Primary biliary cholangitis
• Primary sclerosing cholangitis
Genetic causes




• Budd-Chiari syndrome Fig. 1 Clinical progression of liver disease
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The standard of care for patients with CLD (including
ACLF) revolves around the management of the afore-
mentioned complications of decompensation. There are
currently no disease modifying therapies to reverse or
resolve cirrhosis, currently the only definitive treatment
is LT, the provision of which is limited by shortage of
donor organs, long waiting times, peri-operative compli-
cations, transplant-associated morbidities such as rejec-
tion and immunosuppression, and the allied financial
costs [15, 16]. As a result, the evaluation of novel ther-
apies to improve outcome in patients with CLD is
needed. Emergent therapies include infusing patients
with stem cells to promote liver regeneration and subse-
quently improving liver function and fibrosis.
Information on the intervention
Stem cells
Stem cells are undifferentiated cells that are able to
proliferate in an effectively unlimited fashion [17].
There are two broad types of stem cells with thera-
peutic potential: embryonic stem cells and adult stem
cells [18]. Embryonic stem cells (ESCs) can differenti-
ate into any type of stem cells, but adult stem cells
are less versatile in their differentiation. Stem cells
can be obtained from self (autologous) or from a
donor (allogenic) which can then be used for therapy.
For this review, the main focus will be on adult stem
cells. Mobilisation of stem cells from the bone mar-
row to the peripheral circulation can be induced with
injection of a glycoprotein known as granulocyte
colony-stimulating factor (GCSF).
Research has focused on bone marrow-derived stem
cells in recent years due to ease of harvesting. Harvested
cells can be infused into the patient in a number of
ways, and these include infusion via peripheral vein [19]
or centrally to the liver via the hepatic artery [20] or
portal vein [21].
Several clinical studies have examined the effects of
stem cell therapies in patients with CLD/ACLF [19–22].
These range from early proof of concept studies [23–25]
through to larger randomised controlled trials (RCTs)
[26, 27]. The results of these studies suggest that cell
therapy is safe with no significant adverse events and
has beneficial effects on CLD.
HSC
Haematopoietic stem cells (HSCs) are the only cells
within the haematopoietic system that possess the po-
tential for both multi-potency (ability to differentiate
into many cell lines) and self-renewal (the ability to give
rise to identical daughter HSCs without differentiation)
[28]. HSC are commonly isolated from the blood, bone
marrow, umbilical cord blood or occasionally from per-
ipheral blood on the basis of their expression of specific
surface markers as in CD34+ and CD133+ [19, 29, 30].
Other approaches include the use of unsorted peripheral
blood mononuclear cells which contain HSC amongst
other cell populations [31].
MSC
Mesenchymal stem cell (MSC; also called mesenchymal
stromal cells) is a subset of non-haematopoietic stem
cells [32]. MSC can be obtained from the blood and
bone marrow, but they are also abundant elsewhere such
as the skin, umbilical cord blood, adipose tissue, gut,
lung, placenta, amniotic fluid, tendon, synovial fluid,
skeletal muscle, liver and heart [33, 34]. MSCs have the
potential to differentiate into hepatocytes, reduce hep-
atocyte apoptosis, increase hepatocyte regeneration, and
reduce liver fibrosis by suppressing inflammatory re-
sponses [35]. In this review, MSC obtained from any
source that fits the inclusion criteria will be included.
Unsorted stem cells
Stem cells that are neither haematopoietic or mesenchy-
mal in nature will be classified under unsorted stem
cells. These cell types will include bone marrow mono-
nuclear cells (BM-MNCs) or bone marrow stem cells
(BMSCs).
Granulocyte colony stimulating factor (GCSF)
GCSF is a growth factor that stimulates bone marrow to
produce a large amount of stem cells and release them
into the peripheral blood [36]. GCSF therapy is not only
commonly administered prior to HSC cell harvesting
but also has been investigated as an independent treat-
ment option on its own has been investigated as a treat-
ment option for CLD [37]. The common side effects of
GCSF include flu-like illness, bone pain, fluid retention
and abdominal discomfort or pain due to enlargement
Table 2 Child-Pugh scoring system
Parameters
Bilirubin (umol/L) Albumin (g/dL) Prothrombin time (in seconds) Ascites Hepatic Encephalopathy
1 point <34 >35 <4 None None
2 points 34–50 28–35 4–6 Mild Grades I–II (or suppressed with medication)
3 points >50 <28 >6 Moderate to severe Grades III–IV (or refractory to medication)
Child A, points (5–6), 1-year mortality 100 %; child B, points (7–9), 1-year mortality 81 %; child C, points (10–15), 1-year mortality 45 %
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of the spleen [36]. GCSF is used in mobilising HSC into
the circulation from where they can be isolated for clin-
ical use. GCSF is not used in the isolation of MSC.
Rationale for this review
Scoping searches performed on Cochrane Library
(Cochrane Database of Systematic Review, Database of
Abstracts of Reviews of Effects, Health Technology As-
sessments) and PROSPERO (up to 30/05/2015) identi-
fied five published systematic reviews of cell therapy in
liver disease [26, 27, 38–40] and no in-progress reviews.
Across the five reviews, none were without limitations.
Major and common issues include basic or unclear
search strategies, analysis of different study designs to-
gether, analysis of MSC and HSC therapies together and
lack of clarity on limitations of (or reason for not) con-
ducting meta-analysis or subgroup analysis. It will be
prudent to perform new review because there have been
few new original studies which fit the inclusion criteria
since the last review in 2015 [41] as well as the many
limitations of the current published previous systematic
reviews which mentioned above. Depending on the avail-
ability and nature of the existing evidence subgroup ana-
lyses based on type of stem cell, route of administration
and patient’s underlying liver conditions will be undertaken.
Methods/design
Aims and objectives
The aim of this systematic review is to evaluate the clin-
ical effectiveness of cell therapies in the treatment of pa-
tients with CLD or ACLF. As ACLF is considered a
discrete disease entity within CLD, it is a pre-specified
subgroup for this review. Furthermore, as far as possible,
CLD without ACLF will also be a discrete subgroup.
The proposed systematic review will answer the fol-
lowing main question: when compared to standard ther-
apy what is the clinical effectiveness of (a) HSC, (b)
MSC, (c) unsorted stem cells and (d) GCSF therapy in
the treatment of CLD or ACLF?
Standard systematic review methodology aimed at
minimising bias will be employed. Where data allows,
the intention is to consider, through subgroup analysis,
the evidence of effect in different underlying disease
populations (as in viral hepatitis- or alcohol-related liver
diseases), the effect of each type of stem cells (HSC,
MSC, unsorted stem cell or GCSF therapy alone), the
source of the stem cells (autologous and allogeneic stem
cells) and the route of administration of the cells such as
peripheral or central route.
Determination of comparative effectiveness between
cell types and routes of administration will be consid-
ered if there are direct comparisons in studies included
in the reviews. In addition, the potential for indirect ad-
justed comparisons will be assessed [42].
Type of studies
Controlled trials will be included with no restrictions on
the type of design.
All observational evidence will be obtained, whether
controlled or uncontrolled, in order to gain an overview
of existing observational evidence. Uncontrolled obser-
vational studies will be used where primary outcomes
are not reported in the controlled studies or where uncon-
trolled studies have longer follow-up for these outcomes.
Existing systematic reviews will be selected in order to








(1)Patient with acute liver failure (no evidence of liver
cirrhosis)
(2)Patient with cancer (unable to ascertain the effect of
stem cells on tumour pathogenesis)
Studies on mixed populations of those defined under
inclusion and exclusion criteria will only be included
where the data for CLD or ACLF is presented separately.
Types of interventions
(1)Treatment with HSC of any dose, duration and
mode of delivery with standard medical therapy with
or without GCSF therapy to mobilise stem cells for
collection/harvesting
(2)Treatment with MSC from any source, any dose,
duration and mode of delivery with standard
medical therapy
(3)Treatment with unsorted stem cells (BMSC and/or
BM-MNC) of any dose, duration and mode of
delivery with standard medical therapy with or
without GCSF
(4)Treatment with GCSF therapy only (without stem
cell infusion) of any dose and duration with standard
medical therapy
Comparator
For studies where a comparator arm is included, com-
parators may consist of placebo, standard medical ther-
apy or another treatment intervention listed above
under interventions.
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Types of outcome measures
There will be no restriction placed on the type of clinical
outcomes or the duration of follow-up for study selec-
tion to capture the additional evidence of adverse events
occurring close to the time of stem cell infusion or
GCSF injection. To guide data extraction and analysis,










(3)Events of liver decompensation as defined and
reported by the study authors
Search strategy
Cell therapy in liver diseases was first investigated in
clinical phase studies in early 2000s, and hence, the
searches will be run from year 1990 onwards. The fol-
lowing databases will be searched to capture both pub-
lished and unpublished studies.
1. Bibliographic databases—MEDLINE, MEDLINE in
Process and EMBASE, Cochrane Library CENTRAL
database for published studies and additionally for
systematic reviews the Cochrane Library Database of
Systematic Reviews, Health Technology Assessment
database and the Database of Abstracts of Reviews
of Effects
2. The International Standard Randomised Controlled
Trial Number (ISRCTN) database, United Kingdom
Clinical Research Network (UKCRN), WHO
International Clinical Trials Registry Platform
(WHO ICTRP) Portal and ClinicalTrials.gov for
ongoing studies
3. Hand searching of conference reports from the
following databases between January 2012 and
December 2015: the European Association for the
study of Liver Disease, American association for the
study of liver disease, Asian-Pacific association for
liver disease, British association for the study of liver
disease and British society of gastroenterology
4. Screening of citation lists of included studies and
relevant systematic reviews
The searches of bibliographic databases will employ a
combination of text words and index terms relating to
liver disease and cell therapy as appropriate. There will
be no language restrictions applied to the searches.
Study design filters will not be used. A sample strategy
for MEDLINE is provided in Appendix.
Search results will be entered into electronic database
(ENDNOTE version X7.0.2 Thomson Reuters) to facili-
tate record keeping, duplicate removal, study selection
and document writing.
Data collection and analysis
Selection of studies
To remove irrelevant articles, one reviewer will screen
all the titles and abstracts, and to ensure consistency,
another reviewer will check a proportion (minimum
50 % of all articles) independently. This way of screen-
ing articles is a limitation of the study due to this pro-
ject being unfunded.
Hard copies of relevant articles will be acquired and
assessed independently against the inclusion criteria by
two reviewers. Discrepancies between reviewers will be
resolved by discussion and by referring to a third re-
viewer if required. Full-text selection will be performed
by two reviewers independently. Where necessary, trans-
lation (full/part) of non-English language articles will be
undertaken to facilitate this process and subsequent
reviewing. Where translations are not possible and this
limits selection and/or reviewing, this will be reported.
The study selection process will be illustrated using a
PRISMA flow diagram.
Data extraction and management
Data extraction of the included studies will be per-
formed using a standardised data extraction form by one
reviewer and checked independently by a second re-
viewer for all the studies. Disagreements will be resolved
through discussion or referral to a third reviewer. For
each study, the data required on (but not limited to) the
following will be sought:
1. Study characteristics: authors, geographical origin,
year of publication, study design (to include bias/
confounding minimisation), years and duration of
recruitment, number of arms, sample size and
duration of follow-up
2. Participant characteristics: enrolment criteria, age,
sex, number of participants, diagnosis and disease
manifestations
3. Intervention and comparator details: sample size for
each treatment arm, dose and type of interventions/
comparator (HSC, MSC, unsorted stem cell or GCSF
therapy alone), type of treatment received before or
during therapy and the duration of treatment
4. Results: outcomes measured, time points, method of
assessment, completeness of follow-up, statistical
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methods employed, findings, effect sizes and
associated uncertainty
There are likely to be a limited number of RCT on this
topic, and therefore, as mentioned previously, all obser-
vational evidence will be obtained, whether controlled or
uncontrolled, in order to gain an overview of existing
observational evidence. However, the uncontrolled ob-
servational studies will only be analysed where primary
outcomes are not reported in the controlled studies or
where uncontrolled studies have longer follow-up for
these outcomes. To facilitate this decision-making and
to be efficient, data from controlled studies will be ex-
tracted first and data from uncontrolled studies will only
be extracted initially to determine design, population,
intervention, outcomes and duration of follow-up.
Assessment of risk of bias of included studies
Data will be extracted to allow quality assessment of
the included studies. Study quality will be assessed
using tools specific to a given study design. The risk
of bias tool from the Cochrane Handbook will be
used for RCTs [43]. For non-RCT studies, the do-
mains in the risk of bias tool for RCTs can be used
as a minimum assessment (accepting that the studies
are not randomised).
For controlled observational studies, the guidelines
outlined in Chapter 13 of the Cochrane Handbook
will be followed [43]. The most relevant criteria for
assessment in this area are likely to relate to how the
groups were selected, differences in patient character-
istics, loss to follow-up and biases and confounding
in outcome assessment. Quality assessment for un-
controlled studies will be based on the guidance in
the Centre for Reviews and Dissemination Handbook
[44]. Items for consideration will include selection of
patients (criteria and whether a consecutive series),
detail on those lost to follow-up, use of objective
and/or blinded outcome assessment.
Analysis
Initially, a narrative synthesis of evidence will be under-
taken. This will structure each intervention comparison
relevant to the aims of the review (HSC vs usual care;
MSC vs usual care; unsorted stem cells vs usual care;
GCSF vs usual care) and by outcome and by population
(CLD/ACLF). There will also be stratification by each
study design contributing evidence. Subgroup analysis
will be considered to investigate data on each type of
stem cells, the source of stem cells (allogeneic and au-
tologous) and the route of administration (central or
peripheral infusion),
Data are likely to be presented using different outcome
statistics, for example, mean difference, relative risk, and
hazard ratio. Time points of reporting outcomes are also
likely to vary across studies. Time points of 3 months or
longer will be preferentially analysed to reflect the re-
quirement for data on longer term survival and liver
function. However, shorter term data (<3 months) will
not be ignored as it is likely to relate to underlying
population risk and procedure-related events. The
events will be analysed as per following time points: 0–
3 months, 3–12 months and beyond 12 months. There
will be no time limit for outcomes such as adverse
events and mortality.
Analysis methods will be guided by the considerations
outlined in the Cochrane Handbook [43]. Meta-analytic
methods will be employed where appropriate, to com-
bine data for each population, comparison, outcome
combination across the same or very similar time points.
Summary statistics will most likely be pooled relative
risk for dichotomous outcomes, pooled mean difference
for continuous outcomes or pooled hazard ratios for
time to event data. This may involve conversion of dif-
ferent statistics into a single, consistent measure, where
appropriate assumptions are met, for example, by using
the method of Parmar to obtain hazard ratios from di-
chotomous data [45]. Standardised mean differences will
be considered if the same outcome is measured using
different assessment tools (e.g. quality of life).
Appropriateness of performing meta-analysis and
whether a fixed or random effects model is the most
suitable will be determined by assessment of clinical and
methodological heterogeneity rather than tests of het-
erogeneity from a fixed effects model [46]. The percent-
age of the total variability in the data due to between-
study heterogeneity (I2 statistic) will be reported. Evi-
dence from differing study designs (e.g. RCTs and obser-
vational studies) will not be quantitatively combined, but
presented separately. It is likely that the random effects
model will be the most appropriate for all analyses due
to the underlying heterogeneity. The likelihood of publi-
cation bias will be investigated through the construction
of funnel plots and appropriate statistical tests for small-
study effects for each analysis of primary outcomes
where 10 or more studies contribute data [43, 47].
The potential for sensitivity analysis of meta-analysis
conclusion will be considered, for example, where there
is a clear difference in methodological quality between
studies of a similar design contributing data to a spe-
cific analysis.
As several interventions are considered in this review,
the potential for undertaking adjusted indirect compari-
sons/multiple treatment comparisons will be explored,
for example, where there are RCTs on different types of
stem cell interventions with a common comparator (for
example, HSC vs usual care and MSC vs usual care).
The ability to undertake such analyses will be dependent
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on a number of key assumptions (e.g. the homogeneity,
similarity and consistency assumptions) [48–50].
The findings of each analysis (effect size and preci-
sion) will be considered in conjunction with the meth-
odological quality of the contributing studies, the
variation in effect between studies and the importance
of the outcome measures. The generalisability of find-
ings will be discussed.
Reporting of data
The review and its findings will be reported in accord-
ance with the Preferred Reporting Items for Systematic
Reviews and Meta-Analysis guidelines [51].
Discussion
Liver cirrhosis is a significant cause of mortality world-
wide for which there is no effective therapy except OLT.
However, due to shortage of donor organs, many pa-
tients die whilst waiting for a LT. Hence, cell therapies
have been studied as an alternative treatment option al-
though their clinical effectiveness is still unclear. The
aim of this systematic review is to address whether cell
therapies (or GCSF alone) are effective interventions for
the treatment of CLD and/or ACLF and if the method of
harvesting stem cells or the route of their administration
are effect modifiers. The findings will be of great interest
to clinicians, healthcare decision makers and patients,
and given the emergent nature of the interventions, it
will also inform future research.
Appendix
Database: Ovid MEDLINE(R) <1946 to December week
3 2015>
Search Strategy:
1. exp Acute-On-Chronic Liver Failure/or exp Liver
Diseases/or exp Liver Regeneration/or exp End
Stage Liver Disease/or exp Liver Cirrhosis/
2. liver disease$.ti,ab.
3. liver cirrhosis.ti,ab.
4. acute-on-chronic liver failure.ti,ab.
5. liver regenerat$.ti,ab.
6. exp Hematopoietic Stem Cells/or exp Stem Cells/or
exp Stem Cell Transplantation/or exp Bone
Marrow/
7. exp Mesenchymal Stromal Cells/
8. stem cell$.ti,ab.
9. exp Granulocyte Colony-Stimulating Factor/
10. granulocyte colony stimulating factor.ti,ab.
11.mesenchymal stromal cell.ti,ab.
12. 1 or 2 or 3 or 4 or 5
13. 6 or 7 or 8 or 9 or 10 or 11
14. 12 and 13
15. limit 14 to (humans and yr = "1990 -Current")
Additional file
Additional file 1: PRISMA-P (Preferred Reporting Items for Systematic
review and Meta-Analysis Protocols) 2015 checklist: recommended items
to address in a systematic review protocol*. (DOC 82 kb)
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